Improved three-dimensional free-breathing coronary magnetic resonance angiography using gadocoletic acid (B-22956) for intravascular contrast enhancement.

Details

Serval ID
serval:BIB_E4ECB589C87A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Improved three-dimensional free-breathing coronary magnetic resonance angiography using gadocoletic acid (B-22956) for intravascular contrast enhancement.
Journal
Journal of Magnetic Resonance Imaging
Author(s)
Paetsch I., Huber M.E., Bornstedt A., Schnackenburg B., Boesiger P., Stuber M., Fleck E., Cavagna F., Nagel E.
ISSN
1053-1807[print], 1053-1807[linking]
Publication state
Published
Issued date
2004
Volume
20
Number
2
Pages
288-293
Language
english
Notes
Publication types: Clinical Trial ; Clinical Trial, Phase I ; Comparative Study ; Journal Article
Publication Status: ppublish
Abstract
PURPOSE: To evaluate gadocoletic acid (B-22956), a gadolinium-based paramagnetic blood pool agent, for contrast-enhanced coronary magnetic resonance angiography (MRA) in a Phase I clinical trial, and to compare the findings with those obtained using a standard noncontrast T2 preparation sequence. MATERIALS AND METHODS: The left coronary system was imaged in 12 healthy volunteers before B-22956 application and 5 (N = 11) and 45 (N = 7) minutes after application of 0.075 mmol/kg of body weight (BW) of B-22956. Additionally, imaging of the right coronary system was performed 23 minutes after B-22956 application (N = 6). A three-dimensional gradient echo sequence with T2 preparation (precontrast) or inversion recovery (IR) pulse (postcontrast) with real-time navigator correction was used. Assessment of the left and right coronary systems was performed qualitatively (a 4-point visual score for image quality) and quantitatively in terms of signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), vessel sharpness, visible vessel length, maximal luminal diameter, and the number of visible side branches. RESULTS: Significant (P < 0.01) increases in SNR (+42%) and CNR (+86%) were noted five minutes after B-22956 application, compared to precontrast T2 preparation values. A significant increase in CNR (+40%, P < 0.05) was also noted 45 minutes postcontrast. Vessels (left anterior descending artery (LAD), left coronary circumflex (LCx), and right coronary artery (RCA)) were also significantly (P < 0.05) sharper on postcontrast images. Significant increases in vessel length were noted for the LAD (P < 0.05) and LCx and RCA (both P < 0.01), while significantly more side branches were noted for the LAD and RCA (both P < 0.05) when compared to precontrast T2 preparation values. CONCLUSION: The use of the intravascular contrast agent B-22956 substantially improves both objective and subjective parameters of image quality on high-resolution three-dimensional coronary MRA. The increase in SNR, CNR, and vessel sharpness minimizes current limitations of coronary artery visualization with high-resolution coronary MRA.
Keywords
Adult, Contrast Media, Coronary Vessels/anatomy & histology, Gadolinium/diagnostic use, Humans, Image Processing, Computer-Assisted, Imaging, Three-Dimensional, Inhalation/physiology, Magnetic Resonance Angiography/methods, Male, Organometallic Compounds/diagnostic use
Pubmed
Web of science
Create date
02/03/2010 16:04
Last modification date
20/08/2019 16:08
Usage data